一名接受多模式治疗的转移性神经内分泌前列腺癌长期幸存者：来自二代测序的遗传学考量
A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing.
作者信息
Hongo Hiroshi, Kosaka Takeo, Nakatsuka Seishi, Oya Mototsugu
机构信息
Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582 Japan.
Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan.
出版信息
Int Cancer Conf J. 2021 Apr 13;10(3):174-180. doi: 10.1007/s13691-021-00482-2. eCollection 2021 Jul.
Abstract
UNLABELLED
It is still unclear whether cell-free DNA (cfDNA) can replace solid-tissue biopsy. A 59-year-old man developed castration-resistant prostate cancer with a liver metastasis. We performed a liver biopsy and collected a cfDNA sample. Although he underwent radiofrequency ablation, tumors recurred and he was transferred to another hospital. We performed next-generation sequencing using DNA from the biopsy tissue and cfDNA. BRCA2 p.T3033fs and AURKA F31I were detected in both the biopsy tissue and the cfDNA. cfDNA may be useful as a liquid biopsy for monitoring the gene profile of aggressive prostate cancer.
SUPPLEMENTARY INFORMATION
The online version contains supplementary material available at 10.1007/s13691-021-00482-2.
摘要
未标记
游离DNA（cfDNA）是否能够替代实体组织活检尚不清楚。一名59岁男性患去势抵抗性前列腺癌并伴有肝转移。我们进行了肝脏活检并采集了一份cfDNA样本。尽管他接受了射频消融治疗，但肿瘤复发，随后他被转至另一家医院。我们使用活检组织和cfDNA中的DNA进行了二代测序。在活检组织和cfDNA中均检测到BRCA2 p.T3033fs和AURKA F31I。cfDNA作为一种液体活检手段，可能有助于监测侵袭性前列腺癌的基因图谱。
补充信息
在线版本包含可在10.1007/s13691-021-00482-2获取的补充材料。
相似文献
1
A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing.一名接受多模式治疗的转移性神经内分泌前列腺癌长期幸存者：来自二代测序的遗传学考量
Int Cancer Conf J. 2021 Apr 13;10(3):174-180. doi: 10.1007/s13691-021-00482-2. eCollection 2021 Jul.
2
Aggressive variant prostate cancer with multiple subcutaneous metastases: a case report.侵袭性变异型前列腺癌伴多发皮下转移：一例报告
Int Cancer Conf J. 2024 Apr 18;13(3):250-255. doi: 10.1007/s13691-024-00673-7. eCollection 2024 Jul.
3
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.前列腺癌中循环肿瘤DNA与配对转移组织活检的一致性
J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.
4
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.联合检测游离 DNA 和 RNA 的雄激素受体：一种新型多分析物液体活检检测在转移性前列腺癌中的临床应用。
Eur Urol. 2020 Aug;78(2):173-180. doi: 10.1016/j.eururo.2020.03.044. Epub 2020 May 30.
5
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.循环肿瘤 DNA 丰度及其在初发性转移性前列腺癌中的潜在应用。
Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10.
6
Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.雄激素受体通路抑制剂治疗转移性去势抵抗性前列腺癌患者中总血浆无细胞 DNA 浓度的预后影响。
Eur Urol Focus. 2021 Nov;7(6):1287-1291. doi: 10.1016/j.euf.2020.07.001. Epub 2020 Jul 29.
7
Using circulating cell-free DNA to monitor personalized cancer therapy.利用循环无细胞 DNA 监测个体化癌症治疗。
Crit Rev Clin Lab Sci. 2017 May;54(3):205-218. doi: 10.1080/10408363.2017.1299683. Epub 2017 Apr 10.
8
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.利用靶向54基因二代测序平台对转移性实体瘤患者游离DNA中的体细胞突变检测进行前瞻性盲法研究。
Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.
9
Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.晚期 NSCLC 患者血浆、痰液、尿液与肿瘤组织中游离 DNA 的基因组图谱差异。
Cancer Med. 2019 Mar;8(3):910-919. doi: 10.1002/cam4.1935. Epub 2019 Feb 14.
10
A first Japanese case of and co-loss organ-confined prostate cancer successfully treated by radical prostatectomy.首例日本局限于器官的伴 和 共缺失的前列腺癌经根治性前列腺切除术成功治疗的病例。 （注：原文中“and co-loss”部分内容缺失，导致翻译不太完整准确）
Int Cancer Conf J. 2021 Mar 27;10(3):170-173. doi: 10.1007/s13691-021-00469-z. eCollection 2021 Jul.
引用本文的文献
1
An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.神经内分泌肿瘤铂类化疗敏感性相关改变途径概述：优势与前景。
Int J Mol Sci. 2024 Aug 6;25(16):8568. doi: 10.3390/ijms25168568.
2
G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer.作为卡巴他赛耐药前列腺癌潜在靶点的催产素受体G蛋白信号传导
PNAS Nexus. 2024 Jan 4;3(1):pgae002. doi: 10.1093/pnasnexus/pgae002. eCollection 2024 Jan.
3
From genetic analysis to precision medicine.从基因分析到精准医学。
Int Cancer Conf J. 2021 Jun 11;10(3):159. doi: 10.1007/s13691-021-00492-0. eCollection 2021 Jul.
本文引用的文献
1
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.铂类化疗用于伴有DNA修复基因改变的转移性前列腺癌
JCO Precis Oncol. 2020;4:355-366. doi: 10.1200/po.19.00346. Epub 2020 Apr 16.
2
-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.- 前列腺癌改变：标准全身疗法、聚（ADP - 核糖）聚合酶抑制剂和PD - 1抑制剂的临床特征及治疗结果
JCO Precis Oncol. 2020;4:370-381. doi: 10.1200/po.19.00399. Epub 2020 Apr 21.
3
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.转移性前列腺癌中错配修复缺陷：对 PD-1 阻断和标准疗法的反应。
PLoS One. 2020 May 26;15(5):e0233260. doi: 10.1371/journal.pone.0233260. eCollection 2020.
4
Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy.寡转移癌的放射治疗：意大利伦巴第（AIRO-Lombardy）放射肿瘤学家的一项调查。
Radiol Med. 2019 Apr;124(4):315-322. doi: 10.1007/s11547-018-0972-6. Epub 2018 Dec 15.
5
Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival.结直肠癌转移的局部消融或放射性栓塞治疗：合并症或年龄较大不影响总生存期。
BMC Cancer. 2018 Sep 10;18(1):882. doi: 10.1186/s12885-018-4784-9.
6
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.随机 II 期研究评估 Akt 阻断联合阿比特龙治疗伴有或不伴有 PTEN 缺失的转移性前列腺癌患者的疗效。
Clin Cancer Res. 2019 Feb 1;25(3):928-936. doi: 10.1158/1078-0432.CCR-18-0981. Epub 2018 Jul 23.
7
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.治疗后出现的小细胞神经内分泌前列腺癌的临床和基因组特征：一项多机构前瞻性研究。
J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.
8
Non-small cell neuroendocrine carcinoma of the ovary in a -germline mutation carrier: A case report and brief review of the literature.一位携带种系突变的卵巢非小细胞神经内分泌癌：病例报告及文献简要综述。
Oncol Lett. 2018 Apr;15(4):4093-4096. doi: 10.3892/ol.2018.7836. Epub 2018 Jan 22.
9
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.前列腺癌中循环肿瘤DNA与配对转移组织活检的一致性
J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.
10
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.极光激酶A调节卵巢癌细胞中的非同源末端连接和聚（ADP-核糖）聚合酶功能。
Oncotarget. 2017 Jul 5;8(31):50376-50392. doi: 10.18632/oncotarget.18970. eCollection 2017 Aug 1.
Zotero 插件